Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | TAS2R31 | P59538 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.62 |
| ▸ | XDH | P47989 | 2/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716844 | 0.88 | NPC1 (0.77) | NPC1RAB9ATAS2R31TP53CYP3A4 | |
| SCHEMBL27775449 | 0.87 | NPC1 (0.82) | NPC1RAB9ATAS2R31TP53CYP3A4 | |
| SCHEMBL382207 | 0.86 | TAS2R31 (0.79) | NPC1RAB9ATAS2R31TP53CYP3A4 | |
| Dihydrooroxylin A SCHEMBL31682921 | 0.85 | NPC1 (1.00) | NPC1RAB9ATAS2R31CYP3A4CYP19A1 | |
| Dihydrooroxylin A SCHEMBL12067042 | 0.85 | NPC1 (1.00) | NPC1RAB9ATAS2R31CYP3A4CYP19A1 | |
| SCHEMBL31028356 | 0.84 | CYP19A1 (0.87) | NPC1RAB9ATAS2R31TP53CYP3A4 | |
| SCHEMBL7605704 | 0.84 | TAS2R31 (0.65) | NPC1RAB9ATAS2R31TP53CYP3A4 | |
| SCHEMBL28589889 | 0.83 | TAS2R31 (0.64) | NPC1RAB9ATAS2R31TP53CYP3A4 | |
| SCHEMBL30865912 | 0.83 | TAS2R31 (0.64) | NPC1RAB9ATAS2R31TP53CYP3A4 | |
| SCHEMBL14421486 | 0.83 | TAS2R31 (0.57) | NPC1RAB9ATAS2R31TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277595-A2 | Compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| EP-1765313-A2 | COMPOUNDS FOR IMMUNOPOTENTIATION | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002422-A9 | COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORP (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006002422-A2 | COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-6025387-A | Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease | DONG A PHARMACEUTICAL CO., LTD. (KR) | 2000-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | NPC1 3691/4885RAB9A 1608/4885TAS2R31 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.